ArticleCancer medicine2026

Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.

Min-Hsi Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.